|
Other anticoagulants
Citations 1-10 of 72 total displayed.
|
Most recent content
(15 Apr 2008):
|
- Correspondence
Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women’s Health Study"
- Robert J. Glynn, Paul M Ridker, Robert Y.L. Zee, Julie E. Buring, and Samuel Z. Goldhaber
Circulation 2008; 117: e313, doi:10.1161/CIRCULATIONAHA.107.756437
[Full text]
|
Past content
(since Jan 2001):
|
- Contemporary Reviews in Cardiovascular Medicine
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
- Jack Hirsh, Martin O’Donnell, and John W. Eikelboom
Circulation 2007; 116: 552-560, doi:10.1161/CIRCULATIONAHA.106.685974
[Full text]
- Editorials
A Replacement for Warfarin: The Search Continues
- John W. Eikelboom and Jeffrey I. Weitz
Circulation 116: 131 -133; published online before print as doi:10.1161/CIRCULATIONAHA.107.712349
[Full text]
- Vascular Medicine
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
- Giancarlo Agnelli, Alexander Gallus, Samuel Z. Goldhaber, Sylvia Haas, Menno V. Huisman, Russel D. Hull, Ajay K. Kakkar, Frank Misselwitz, Sebastian Schellong for the ODIXa-DVT Study Investigators
Circulation 116: 180 -187; published online before print as doi:10.1161/CIRCULATIONAHA.106.668020
[Abstract]
[Full text]
- Articles
A Replacement for Warfarin. The Search Continues
- John W. Eikelboom and Jeffrey I. Weitz
Circulation published June 18, 2007, doi:10.1161/CIRCULATIONAHA.107.712349
[Abstract]
- Articles
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
- Giancarlo Agnelli, Alexander Gallus, Samuel Z. Goldhaber, Sylvia Haas, Menno V. Huisman, Russel D. Hull, Ajay K. Kakkar, Frank Misselwitz, Sebastian Schellong for the ODIXa-DVT Study Investigators
Circulation published June 18, 2007, doi:10.1161/CIRCULATIONAHA.106.668020
[Abstract]
- Coronary Heart Disease
Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction
- Jessica L. Mega, David A. Morrow, Erika Östör, Maria Dorobantu, Jie Qin, Elliott M. Antman, and Eugene Braunwald
Circulation 115: 2822 -2828; published online before print as doi:10.1161/CIRCULATIONAHA.106.679548
[Abstract]
[Full text]
- Interventional Cardiology
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial
- Marc Cohen, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, Jan Saaiman, Stanislas Simek, Johannes De Swart on behalf of the SEPIA-PCI Trial Investigators
Circulation 115: 2642 -2651; published online before print as doi:10.1161/CIRCULATIONAHA.106.653428
[Abstract]
[Full text]
- Articles
Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction
- Jessica L. Mega, David A. Morrow, Erika Östör, Maria Dorobantu, Jie Qin, Elliott M. Antman, and Eugene Braunwald
Circulation published May 21, 2007, doi:10.1161/CIRCULATIONAHA.106.679548
[Abstract]
- Articles
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial
- Marc Cohen, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, Jan Saaiman, Stanislas Simek, Johannes De Swart on behalf of the SEPIA-PCI Trial Investigators
Circulation published May 14, 2007, doi:10.1161/CIRCULATIONAHA.106.653428
[Abstract]
|
|
